<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983034</url>
  </required_header>
  <id_info>
    <org_study_id>20061976</org_study_id>
    <nct_id>NCT00983034</nct_id>
  </id_info>
  <brief_title>The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy</brief_title>
  <official_title>Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections,
      drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori
      (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the
      prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria
      level in patients with MN will be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. It is thought
      to be mainly a primary or idiopathic form; however, it may also be secondary to many other
      diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the
      presence of Helicobacter Pylori antigen was investigated in renal tissue from needle biopsy
      samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication
      on proteinuria level in patients with MN will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily proteinuria levels after Helicobacter Pylori eradication treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Glomerulonephritis</condition>
  <condition>Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Membranous nephropathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with primary membranous nephropathy diagnosed by biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgA nephropathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with IgA nephropathy diagnosed by biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Focal segmental glomerulosclerosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole, amoxicillin, clarithromycin</intervention_name>
    <description>lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days</description>
    <arm_group_label>Membranous nephropathy</arm_group_label>
    <arm_group_label>IgA nephropathy</arm_group_label>
    <arm_group_label>Focal segmental glomerulosclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-70 years

          -  Nondiabetic patients

          -  Patients with primary glomerulonephritis

          -  Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental
             glomerulosclerosis confirmed by biopsy

          -  Glomerular filtration rate &gt; 30 mL/min

          -  Patients who did not receive Helicobacter pylori eradication therapy within the last
             three months before enrollment in study

        Exclusion Criteria:

          -  Patients with secondary glomerulonephritis

          -  Glomerular filtration rate &lt; 30 mL/min

          -  Patients who received Helicobacter pylori eradication therapy within the last three
             months before enrollment in study

          -  Patients with a history of gastric surgery

          -  Patients without an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasar Caliskan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berna Yelken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halil Yazici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet S Sever, Prof MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>September 22, 2009</last_update_submitted>
  <last_update_submitted_qc>September 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yasar Caliskan</name_title>
    <organization>Division of Nephrology, Department of Intenal Medicine, Istanbul Faculty of Medicine, Istanbul University</organization>
  </responsible_party>
  <keyword>nephrotic syndrome</keyword>
  <keyword>Helicobacter pylori infection</keyword>
  <keyword>proteinuria</keyword>
  <keyword>membranous nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

